Suppr超能文献

吲哚菁绿作为兔视网膜静脉插管及注射组织型纤溶酶原激活剂的有用导向剂。

Indocyanine green as useful guide for retinal vein cannulation and injection of tissue plasminogen activator in rabbits.

作者信息

Suzuki Kaori, Suzuki Yukihiko, Mizukoshi Sayuri, Metoki Tomomi, Nakazawa Mitsuru

机构信息

Department of Ophthalmology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

出版信息

Tohoku J Exp Med. 2008 Apr;214(4):351-8. doi: 10.1620/tjem.214.351.

Abstract

Central retinal vein occlusion (CRVO) is caused by a fibrin clot in central retinal vein and is one of the intractable diseases that deteriorate visual acuities. Tissue plasminogen activator (TPA) is a thrombolytic agent that has a high affinity for fibrin and that activates plasminogen into plasmin. Injection of TPA into the retinal vein was helpful to treat CRVO. But TPA injection into retinal vein was difficult for clinical use, because TPA solution was transparent and confirmation of its injection was not easy. Indocyanine green (ICG) has been used as an angiographic agent and a tissue-marking agent in ocular surgeries. We studied the effectiveness and safety of ICG assisted injection of TPA into the retinal vein in rabbits. The major retinal vein was punctured using a micropipette fabricated from a glass tube, then TPA/ICG was injected. Total of 12 eyes and 5 eyes were enucleated 7 days and 1 month after injection of TPA/ICG for histological observations including immunostaining of glial fibrillary acidic protein (GFAP) and TUNEL staining, respectively. GFAP is expressed in Müller cells under pathologic conditions and indicates retinal damages. TUNEL indicates apoptosis of sensory retina cells. Retinal vein cannulation was easily performed, as retinal vein became green following injection of TPA/ICG. Histologically, no retinal damages, due to the TPA/ICG solution, were observed. GFAP and TUNEL staining were negative. TPA/ICG causes no disturbance in retinal circulation when performed correctly. Because of its safety, ICG is a useful agent as a guide for retinal vein injection of TPA.

摘要

视网膜中央静脉阻塞(CRVO)是由视网膜中央静脉内的纤维蛋白凝块引起的,是导致视力下降的难治性疾病之一。组织型纤溶酶原激活剂(TPA)是一种溶栓剂,对纤维蛋白具有高亲和力,并能将纤溶酶原激活为纤溶酶。向视网膜静脉注射TPA有助于治疗CRVO。但向视网膜静脉注射TPA在临床应用中存在困难,因为TPA溶液是透明的,不容易确认其注射情况。吲哚菁绿(ICG)已被用作眼科手术中的血管造影剂和组织标记剂。我们研究了ICG辅助向兔视网膜静脉注射TPA的有效性和安全性。使用由玻璃管制成的微量移液器穿刺主要视网膜静脉,然后注射TPA/ICG。分别在注射TPA/ICG后7天和1个月摘除12只眼和5只眼进行组织学观察,包括胶质纤维酸性蛋白(GFAP)免疫染色和TUNEL染色。GFAP在病理条件下在Müller细胞中表达,表明视网膜损伤。TUNEL表明感觉视网膜细胞的凋亡。由于注射TPA/ICG后视网膜静脉变绿,因此视网膜静脉插管很容易进行。组织学上,未观察到TPA/ICG溶液引起的视网膜损伤。GFAP和TUNEL染色均为阴性。正确操作时,TPA/ICG不会干扰视网膜循环。由于其安全性,ICG是一种有用的试剂,可作为TPA视网膜静脉注射的引导剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验